Antidiabetika, insulinresistens og hjerte-kar-sygdom hos patienter med type 2-diabetes

Bianca Hemmingsen; Søren S Lund; Allan Vaag

Antidiabetika, insulinresistens og hjerte-kar-sygdom hos patienter med type 2-diabetes

Translated title of the contribution: Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes

Bianca Hemmingsen, Søren S Lund, Allan Vaag

Department of Clinical Medicine

Abstract

This article reviews the current evidence of effects on cardiovascular disease (CVD) of anti-diabetic treatment which exert their effect by increasing the insulin sensitivity in patients with type 2 diabetes (T2D). In overweight T2D patients, it has been demonstrated that metformin reduces the CVD risk. The effect of glitazones on CVD is uncertain. There is insufficient evidence to support a protective effect on CVD of lowering blood-glucose per se. In contrast, lowering blood glucose appears to decrease the risk of microvascular complications.
Udgivelsesdato: 2009-May-4

Translated title of the contribution	Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes
Original language	Danish
Journal	Ugeskrift for læger
Volume	171
Issue number	19
Pages (from-to)	1598-602
Number of pages	4
ISSN	0041-5782
Publication status	Published - 2009

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{3d56e61068c711df928f000ea68e967b,

title = "Antidiabetika, insulinresistens og hjerte-kar-sygdom hos patienter med type 2-diabetes",

abstract = "This article reviews the current evidence of effects on cardiovascular disease (CVD) of anti-diabetic treatment which exert their effect by increasing the insulin sensitivity in patients with type 2 diabetes (T2D). In overweight T2D patients, it has been demonstrated that metformin reduces the CVD risk. The effect of glitazones on CVD is uncertain. There is insufficient evidence to support a protective effect on CVD of lowering blood-glucose per se. In contrast, lowering blood glucose appears to decrease the risk of microvascular complications. Udgivelsesdato: 2009-May-4",

author = "Bianca Hemmingsen and Lund, {S{\o}ren S} and Allan Vaag",

note = "Keywords: Arteriosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Combinations; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Risk Factors; Sulfonylurea Compounds; Thiazolidinediones",

year = "2009",

language = "Dansk",

volume = "171",

pages = "1598--602",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "19",

}

TY - JOUR

T1 - Antidiabetika, insulinresistens og hjerte-kar-sygdom hos patienter med type 2-diabetes

AU - Hemmingsen, Bianca

AU - Lund, Søren S

AU - Vaag, Allan

N1 - Keywords: Arteriosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Combinations; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Risk Factors; Sulfonylurea Compounds; Thiazolidinediones

PY - 2009

Y1 - 2009

N2 - This article reviews the current evidence of effects on cardiovascular disease (CVD) of anti-diabetic treatment which exert their effect by increasing the insulin sensitivity in patients with type 2 diabetes (T2D). In overweight T2D patients, it has been demonstrated that metformin reduces the CVD risk. The effect of glitazones on CVD is uncertain. There is insufficient evidence to support a protective effect on CVD of lowering blood-glucose per se. In contrast, lowering blood glucose appears to decrease the risk of microvascular complications. Udgivelsesdato: 2009-May-4

AB - This article reviews the current evidence of effects on cardiovascular disease (CVD) of anti-diabetic treatment which exert their effect by increasing the insulin sensitivity in patients with type 2 diabetes (T2D). In overweight T2D patients, it has been demonstrated that metformin reduces the CVD risk. The effect of glitazones on CVD is uncertain. There is insufficient evidence to support a protective effect on CVD of lowering blood-glucose per se. In contrast, lowering blood glucose appears to decrease the risk of microvascular complications. Udgivelsesdato: 2009-May-4

M3 - Tidsskriftartikel

C2 - 19419642

SN - 0041-5782

VL - 171

SP - 1598

EP - 1602

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 19

ER -